Showing results (81-90 of 124) with videos related to

Sort By:
Pageof 13
Cytometry. Part B, Clinical Cytometry|March 17, 2009
A rapid flow cytometric screening test for X-linked lymphoproliferative disease due to XIAP deficiencyRebecca A Marsh, Joyce Villanueva, Kejian Zhang, et al.
Pediatric Blood & Cancer|April 24, 2012
Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumabRebecca A Marsh, Carl E Allen, Kenneth L McClain, et al.
The Journal of Clinical Investigation|September 18, 2009
Restimulation-induced apoptosis of T cells is impaired in patients with X-linked lymphoproliferative disease caused by SAP deficiencyAndrew L Snow, Rebecca A Marsh, Scott M Krummey, et al.
EULAR Rheumatology Open|August 1, 2026
Early management of hemophagocytic lymphohistiocytosis/macrophage activation syndrome: a systematic literature reviewDimitri Poddighe, Bita Shakoory, Ashley V Geerlinks, et al.
Journal of Human Immunity|May 22, 2026
A systematic literature review of CVID reveals pervasive detrimental noninfectious manifestationsG Michelle Ducasa, Rebecca A Marsh, Ali Mojebi, et al.
Transplantation and Cellular Therapy|February 24, 2024
Ruxolitinib Pharmacokinetics and Pharmacodynamics in Children with Acute and Chronic Graft-versus-Host DiseaseEleanor Cook, Min Dong, Samuel C C Chiang, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 17, 2013
An intermediate alemtuzumab schedule reduces the incidence of mixed chimerism following reduced-intensity conditioning hematopoietic cell transplantation for hemophagocytic lymphohistiocytosisRebecca A Marsh, Mi-Ok Kim, Chunyan Liu, et al.
Blood|January 29, 2021
T-cell activation profiles distinguish hemophagocytic lymphohistiocytosis and early sepsisVandana Chaturvedi, Rebecca A Marsh, Adi Zoref-Lorenz, et al.
Haematologica|September 2, 2017
HIF1A is a critical downstream mediator for hemophagocytic lymphohistiocytosisRui Huang, Yoshihiro Hayashi, Xiaomei Yan, et al.
Bone Marrow Transplantation|April 11, 2020
CCR5 inhibitor as novel acute graft versus host disease prophylaxis in children and young adults undergoing allogeneic stem cell transplant: results of the phase II studyPooja Khandelwal, Tsuyoshi Fukuda, Ashley Teusink-Cross, et al.
Pageof 13